Name: UMIN ID:
Unique ID issued by UMIN | UMIN000008947 |
---|---|
Receipt number | R000010491 |
Scientific Title | Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer. |
Date of disclosure of the study information | 2012/09/19 |
Last modified on | 2018/09/20 08:27:44 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/09/19 23:12:25 | ||
2 | Update | 2012/10/10 14:32:05 | Email1 |
|
3 | Update | 2013/09/01 17:06:26 | TEL Last name of contact person Last name of contact person TEL |
|
4 | Update | 2014/02/03 22:04:28 | Recruitment status |
|
5 | Update | 2016/04/04 15:04:49 | Address Address TEL Name of primary person or sponsor Organization |
|
6 | Update | 2018/02/05 17:36:43 | Email |
|
7 | Update | 2018/08/06 12:06:50 | Recruitment status Publication of results Results |
|
8 | Update | 2018/09/20 08:26:38 | Recruitment status Results Results |
|
9 | Update | 2018/09/20 08:27:44 | Results Results |